Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midostaurin vs placebo added to intensive chemotherapy in newly diagnosed FLT3-mutated AML (phase III)
2006-006852-37Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Midostaurin arm with Placebo arm (2 arms). Primary endpoint: Overall survival. Started May 2008; status: completed.
02
Drugs
midostaurin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2006-006852-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006852-37.